NEWTOWN SQUARE, PA — ArriVent BioPharma Inc. (Nasdaq: AVBP) reported a $133.5 million net loss for the first nine months of 2026, up from $130.8 million a year earlier, as the Newtown Square biotechnology company continued funding cancer drug development following a late-stage clinical trial that failed to meet its primary endpoint.
The company ended September with $393.2 million in cash and investments, which it expects will support operations through mid-2028. ArriVent is continuing enrollment in a separate Phase 3 lung cancer study while expanding clinical development of two experimental antibody-drug conjugates.
Net cash used in operating activities declined to $122.2 million during the nine months ended September 30, compared with $129.9 million during the same period in 2025.
Research and development expenses totaled $118.9 million, down from $121.2 million a year earlier. General and administrative expenses increased to $28.3 million from $17.5 million.
The financial results come as ArriVent evaluates the future of firmonertinib, its investigational treatment for certain forms of non-small cell lung cancer, following mixed results from the Phase 3 FURVENT trial.
FURVENT failed to meet its primary endpoint of progression-free survival as assessed by blinded independent central review, a setback for the company’s late-stage oncology program.
Patients receiving firmonertinib at a 240-milligram dose achieved median progression-free survival of 11 months, compared with 9.5 months among patients receiving chemotherapy. The difference did not meet the trial’s threshold for statistical significance, with a hazard ratio of 0.75 and a p-value of 0.0654.
The treatment produced a confirmed objective response rate of 60%, compared with 33% for chemotherapy, indicating antitumor activity despite the unsuccessful primary endpoint.
ArriVent is reviewing the complete FURVENT dataset, including differences between independent and investigator assessments of progression-free survival in the chemotherapy group. The company expects to provide an update on its evaluation during the first quarter of 2027.
“While FURVENT did not meet its primary endpoint, firmonertinib demonstrated clear antitumor activity, with an efficacy and safety profile consistent with prior studies,” Chief Executive Officer Bing Yao said.
The company is separately advancing firmonertinib through its global Phase 3 ALPACCA trial, which targets patients with previously untreated non-small cell lung cancer carrying EGFR PACC mutations.
ALPACCA is evaluating firmonertinib at 240 milligrams against investigators’ choice of osimertinib or afatinib, two existing targeted cancer treatments.
The study includes an interim analysis of objective response rates that could support a potential accelerated approval application, while progression-free survival will be evaluated as a basis for potential full regulatory approval.
Enrollment in ALPACCA remains on track, according to the company.
Beyond firmonertinib, ArriVent is expanding its antibody-drug conjugate portfolio, which combines cancer-targeting antibodies with drugs designed to destroy tumor cells.
The company presented preliminary Phase 1 results for ARR-217, also known as MRG007, at the European Society for Medical Oncology Congress 2026.
ARR-217 targets CDH17, a protein associated with certain gastrointestinal cancers, and is being developed in partnership with Lepu Biopharma.
Among evaluable colorectal cancer patients receiving the treatment at 6 milligrams per kilogram, the objective response rate was 44.8%, including confirmed and unconfirmed responses. The disease control rate was 93.1%.
Reported adverse events were predominantly low-grade gastrointestinal and hematologic toxicities.
ArriVent is continuing Phase 1b dose optimization and expansion studies, with additional data expected during the first half of 2027.
The company also anticipates results from ARR-217 combination studies with bevacizumab and chemotherapy during the second half of 2027.
A second antibody-drug conjugate, ARR-002, has entered clinical testing in the United States following treatment of the first patient in a Phase 1a/1b study.
The experimental therapy targets both MUC16 and NaPi2b, proteins associated with certain cancers. Initial development is focused on patients with advanced or metastatic ovarian and endometrial cancers.
The study will assess safety, dosing and preliminary evidence of antitumor activity.
ArriVent also made changes to its clinical leadership, appointing Priti Patel, M.D., M.S., as chief medical officer.
Patel previously held senior oncology development positions at AstraZeneca, Acerta and Onyx Pharmaceuticals. She also served as chief medical officer at Neoleukin Therapeutics and vice president and head of hematology clinical development at AstraZeneca.
The appointment accompanies the retirement of Stuart Lutzker, M.D., Ph.D., an ArriVent co-founder who served as president of research and development and a board member over the past five years.
Lutzker directed the company’s research and development operations and helped establish its antibody-drug conjugate portfolio, including advancing ARR-217 and ARR-002 into clinical testing.
ArriVent’s immediate development priorities now center on continued enrollment in ALPACCA, determining the implications of the unsuccessful FURVENT primary endpoint and generating additional clinical evidence for its antibody-drug conjugate programs.
With $393.2 million in available cash and investments at the end of September, the company expects to fund those activities through mid-2028 while approaching several clinical milestones in 2027.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.
